Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 1-Year Low - Here's What Happened

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $57.04 and last traded at $57.04, with a volume of 445 shares trading hands. The stock had previously closed at $57.28.

Analysts Set New Price Targets

Separately, William Blair upgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.

Zealand Pharma A/S Trading Up 1.9%

The firm has a 50-day moving average of $65.64 and a 200 day moving average of $82.69. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of -22.53 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. As a group, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.